Added to YB: 2025-10-16
Pitch date: 2025-10-14
CARM [neutral]
Carisma Therapeutics, Inc.
+70.15%
current return
Author Info
The Value Road is a deep value investor that's interested in post bankruptcy, NAV, and undervalued micro and nano-cap stocks. I only invest in companies that have layers of value behind them, usually with little or no debt. Sign up for their newsletter.
Company Info
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States.
Market Cap
$2.0M
Pitch Price
$0.03
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.05
P/E
-0.04
EV/Sales
0.16
Sector
Biotechnology
Category
special_situation
The 41% Signal: How Strategic Reviews Hint at Hidden Takeovers - Carisma Therapeutics, Inc.
CARM (strategic review): Board approved strategic alternatives review amid $7M mcap, $5M EV, $12M cash. Options include reverse merger, cell-therapy IP sale/pharma collab, or liquidation. Transaction could revalue equity several-fold; otherwise dilution inevitable.
Read full article (1 min)